{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell&page=8", "query": { "condition": "Clear Cell", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 505, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T23:22:14.241Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00025467", "title": "Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenoacanthoma", "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Cell Carcinoma", "Endometrial Clear Cell Carcinoma", "Endometrial Papillary Serous Carcinoma", "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 60, "start_date": "2001-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025467" }, { "nct_id": "NCT05001282", "title": "A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Endometrial Cancer", "Ovary Cancer", "Ovary Neoplasm", "Ovary Disease", "Ovary Metastasis", "Ovarian Diseases", "Ovarian Cancer Stage", "Ovarian Epithelial Cancer", "Ovarian Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Neoplasm Epithelial", "Ovarian Cancer Recurrent", "Endometrial Diseases", "Endometrial Adenocarcinoma", "Endometrial Carcinosarcoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrioid Adenocarcinoma", "Endometrial Neoplasms", "Endometrial Cancer Recurrent", "Endometrioid Tumor", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "ELU001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elucida Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-09-13", "completion_date": "2024-06-07", "has_results": false, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001282" }, { "nct_id": "NCT02307474", "title": "A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-09", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-03-03", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02307474" }, { "nct_id": "NCT00807768", "title": "Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Fatigue", "Neurotoxicity Syndrome", "Obesity", "Stage I Uterine Corpus Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Internal Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 601, "start_date": "2009-03-23", "completion_date": null, "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 533, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00807768" }, { "nct_id": "NCT06794229", "title": "Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Renal Cell Carcinoma" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qian Qin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2025-10-30", "completion_date": "2029-06-06", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 4, "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania • Dallas, Texas + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06794229" }, { "nct_id": "NCT02501954", "title": "Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Uterine Corpus Cancer", "Stage IVA Uterine Corpus Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Women's Cancer Care Associates, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2015-03", "completion_date": "2023-11", "has_results": false, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Traverse City, Michigan • Morristown, New Jersey + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Traverse City", "state": "Michigan" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Albany", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02501954" }, { "nct_id": "NCT00392769", "title": "Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 33, "start_date": "2006-10", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-09-06", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392769" }, { "nct_id": "NCT03866382", "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Clear Cell Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Neuroendocrine Carcinoma", "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Invasive Bladder Giant Cell Urothelial Carcinoma", "Invasive Bladder Lymphoepithelioma-Like Carcinoma", "Invasive Bladder Nested Urothelial Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Bladder Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Large Cell Neuroendocrine Carcinoma", "Malignant Testicular Leydig Cell Tumor", "Malignant Testicular Sertoli Cell Tumor", "Metastatic Bladder Carcinoma", "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Bladder Large Cell Neuroendocrine Carcinoma", "Metastatic Bladder Lipid-Rich Urothelial Carcinoma", "Metastatic Bladder Micropapillary Urothelial Carcinoma", "Metastatic Bladder Plasmacytoid Urothelial Carcinoma", "Metastatic Bladder Sarcomatoid Urothelial Carcinoma", "Metastatic Bladder Small Cell Neuroendocrine Carcinoma", "Metastatic Bladder Squamous Cell Carcinoma", "Metastatic Chromophobe Renal Cell Carcinoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Genitourinary System Neoplasm", "Metastatic Papillary Renal Cell Carcinoma", "Metastatic Penile Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Metastatic Urethral Carcinoma", "Papillary Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Urachal Adenocarcinoma", "Urethral Clear Cell Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2019-05-13", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 581, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866382" }, { "nct_id": "NCT06026410", "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors With HRAS Alterations", "Non Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Clear Cell Renal Cell Carcinoma (ccRCC)", "Renal Cell Carcinoma (Kidney Cancer)", "Non Clear Cell Renal Cell Carcinoma (nccRCC)" ], "interventions": [ { "name": "Darlifarnib", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Adagrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-10-18", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06026410" }, { "nct_id": "NCT06191796", "title": "Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors" ], "interventions": [ { "name": "zanzalintinib", "type": "DRUG" }, { "name": "AB521", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-01-25", "completion_date": "2025-05-12", "has_results": false, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-11-14T23:22:14.241Z", "location_count": 14, "location_summary": "Los Angeles, California • Miami, Florida • Orlando, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Scarborough", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT06191796" } ] }